UNSPSC 51313436: Pheniramine hydrochloride

This classification denotes a histamine-1 receptor antagonist C16H20N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10P41DI6MI, chemically known as n,n-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine hydrochloride, but more generally known as pheniramine hydrochloride, which bears US NIH Compound Identifier 91402. Most nations, for tariff and trade purposes, schedule pheniramine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PHENIRAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: CN(C)CCC(C1CCCCC1)C2CCCCN2.CL.

UNSPSC 51313436 Pheniramine hydrochloride, a Commodity code, does not align with the state and local procurement activity recently tagged under it. The three most recent opportunities solicited under this code cover naloxone and drug deactivation systems, a direct-to-manufacturer prescription program framework, and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle — none of which are pheniramine hydrochloride specifically. The mismatch suggests that pheniramine may be one of many pharmaceutical inputs in broader acquisitions, or that the source data contains classification errors. State and local governments acquiring under this code are doing so primarily through two structures: direct county procurement (Seminole County, Florida) and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon, and the Texas Health and Human Services Commission). The scope of actual purchasing activity spans acute-care pharmaceuticals (naloxone), pharmacy benefit program optimization, and standing contracts for generic and OTC products distributed through authorized pharmaceutical wholesalers.

Recent activity concentrates in Florida and the Upper Midwest and Texas, with the most concrete solicitation being Seminole County's IFB60459723LAS (posted June 30, 2026; due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Minnesota Department of Administration's MMCAP cooperative vehicle issued RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products available through three authorized wholesalers, with awards effective July 1, 2026; evaluation weights heavily price competitiveness at 75 percent. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) represents exploratory market intelligence on direct-to-manufacturer prescription models rather than a binding acquisition. The Seminole County IFB requires E-Verify compliance, drug-free workplace certification, and specific insurance coverage including $5 million commercial general liability; the MMCAP RFP mandates cGMP and Drug Supply Chain Security Act compliance with performance penalties ranging from $200 to $1,500 per violation.